Daratumumab (DARZALEX & #174;) Granted Breakthrough Therapy Designation by U.S. FDA for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma

FDA action underscores potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for patients who have received at least one prior therapy. Marks the second Breakthrough Therapy Designation for daratumumab

Source: International Myeloma Foundation - July 26, 2016 Category: Hematology Source Type: news